Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person 18-38% percent of neuroblastomas show amplification of the M...
| Class:Id | Summation:9725112 |
|---|---|
| _displayName | 18-38% percent of neuroblastomas show amplification of the M... |
| _timestamp | 2021-03-30 15:10:44 |
| created | [InstanceEdit:9725113] Rothfels, Karen, 2021-03-28 |
| modified | [InstanceEdit:9725359] Rothfels, Karen, 2021-03-29 [InstanceEdit:9725652] Rothfels, Karen, 2021-03-30 |
| text | 18-38% percent of neuroblastomas show amplification of the MYCN gene, while the majority of familial and 10% of sporadic neuroblastomas carry activating mutations in the ALK kinase domain (Mosse et al, 2008; reviewed in Aygun, 2018; Roskoski, 2013). Amplifications of the ALK gene have also been reported in this disease (Caren et al, 2008). ALK and MYCN may play cooperative roles in driving progression of neuroblastoma (Zhu et al, 2012; Mosse et al, 2008; reviewed in Roskoski, 2013). High levels of ALK expression are seen in MYCN amplified neuroblastomas, and inhibition of ALK activity with tyrosine kinase inhibitors in a MYCN-amplified background reduces proliferation, cell migration and tumor growth in xenograft models, suggesting that ALK activity contributes to the oncogenic potential of MYCN-driven neuroblastomas (Hasan et al, 2013; reviewed in Hallberg and Palmer, 2013). |
| (summation) | [BlackBoxEvent:9725117] ALK gene expression [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by 18-38% percent of neuroblastomas show amplification of the M... (9725112)
